At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02171 CARSGEN-B
Trading 07-17 13:15:09
15.020
-2.060
-12.06%
High17.080Low14.700Vol3.35M
Open17.080D1 Closing17.080Amplitude13.93%
Mkt Cap8.92BTradable Cap8.92BTotal Shares594.00M
T/O51.66MT/O Rate0.56%Tradable Shares594.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜CARsgen Therapeutics-B Falls 6.03% in Regular Trading, Biotech Sector Under Broad Selling Pressure
Market Focus  ·  10:04
Movement Alert｜CARsgen Therapeutics-B Falls 6.03% in Regular Trading, Biotech Sector Under Broad Selling Pressure
CARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog
Deep News  ·  07-16 11:50
CARSGEN-B Shares Surge Over 7% in Session as CT041 Passes Initial Review for 2026 Commercial Health Insurance Innovation Drug Catalog
Movement Alert｜CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation
Market Focus  ·  07-16 10:28
Movement Alert｜CARsgen Therapeutics-B Rises 5.51% in Regular Trading, Kelimei Post-Surgical Consolidation Therapy Positive Results Accepted for ESMO Poster Presentation
Hong Kong Stocks Midday Update: Hang Seng Index Rises 1.46%, Innovation Pharma Soars
Stock News  ·  07-15 12:12
Hong Kong Stocks Midday Update: Hang Seng Index Rises 1.46%, Innovation Pharma Soars
Shares of CARSGEN-B Surge Over 6% Ahead of Key Study Presentation at 2026 ESMO Congress
Stock News  ·  07-15 10:56
Shares of CARSGEN-B Surge Over 6% Ahead of Key Study Presentation at 2026 ESMO Congress
Movement Alert｜CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation
Market Focus  ·  07-15 10:43
Movement Alert｜CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation
CARsgen’s Satri-cel Shows No Post-operative Recurrence in IIT; Data Accepted for Presentation at ESMO 2026
Bulletin Express  ·  07-15 08:21
CARsgen’s Satri-cel Shows No Post-operative Recurrence in IIT; Data Accepted for Presentation at ESMO 2026
Carsgen Says Satri-cel Gastric Cancer Consolidation Trial Shows no Recurrences to Date
Reuters  ·  07-15 08:00
Carsgen Says Satri-cel Gastric Cancer Consolidation Trial Shows no Recurrences to Date
Carsgen Files HKEX Next-day Disclosure Return Reporting Share Repurchase and Cancellation
Reuters  ·  07-07
Carsgen Files HKEX Next-day Disclosure Return Reporting Share Repurchase and Cancellation
CARsgen Keeps Share Structure Steady in June 2026; 17.68 Million Options Remain Outstanding
Bulletin Express  ·  07-07
CARsgen Keeps Share Structure Steady in June 2026; 17.68 Million Options Remain Outstanding
Movement Alert｜CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns
Market Focus  ·  07-07
Movement Alert｜CARsgen Therapeutics-B Falls 5.13% in Regular Trading, Strategic Pivot Away from Autologous CAR-T Pipeline Sparks Market Concerns
CARsgen Therapeutics (SEHK:2171) Is Up 20.8% After First Solid Tumor CAR T Approval - What's Changed
Simply Wall St.  ·  07-04
CARsgen Therapeutics (SEHK:2171) Is Up 20.8% After First Solid Tumor CAR T Approval - What's Changed
Movement Alert｜CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound
Market Focus  ·  07-03
Movement Alert｜CARsgen Therapeutics-B Rises 5.14% in Regular Trading, Buyback Plan and Biotech Sector Strength Fuel Rebound
Movement Alert｜CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound
Market Focus  ·  07-02
Movement Alert｜CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced?
Simply Wall St.  ·  06-30
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced?
Movement Alert｜CARsgen Therapeutics-B Rises 6.31% in Regular Trading, Buyback Plan and Sector Recovery Fuel Rebound
Market Focus  ·  06-29
Movement Alert｜CARsgen Therapeutics-B Rises 6.31% in Regular Trading, Buyback Plan and Sector Recovery Fuel Rebound
CARSGEN-B Shares Surge in Afternoon Trading Following Share Buyback Plan Announcement
Stock News  ·  06-26
CARSGEN-B Shares Surge in Afternoon Trading Following Share Buyback Plan Announcement
Carsgen Therapeutics Climbs on Board Nod for Share Buyback
Reuters  ·  06-26
Carsgen Therapeutics Climbs on Board Nod for Share Buyback
CARSGEN-B Announces Share Buyback Plan of Up to 5% of Issued Shares
Stock News  ·  06-26
CARSGEN-B Announces Share Buyback Plan of Up to 5% of Issued Shares
Carsgen Therapeutics Holdings - Approves Share Repurchase Plan for up to 30.12 Mln Shares, About 5% of Issued Shares
THOMSON REUTERS  ·  06-26
Carsgen Therapeutics Holdings - Approves Share Repurchase Plan for up to 30.12 Mln Shares, About 5% of Issued Shares

Introduction

Company Name.
CARSGEN-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.
Issue price:
--